NRx Pharmaceuticals Announces FDA Permission to Proceed on Investigational New Drug Application for NRX-101 to Treat Chronic Pain
RADNOR, PA — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) recenlty announced that FDA has given the company clearance to proceed with human trials to treat Chronic Pain under the Investigational New Drug (IND) …
NRx Pharmaceuticals Announces FDA Permission to Proceed on Investigational New Drug Application for NRX-101 to Treat Chronic Pain Read More